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Glossary 
AJCC: American Joint Committee on Cancer 
SCC: Squamous Cell Carcinoma 
CIS: Carcinoma in situ 
BWH: Brigham and Women’s Hospital 
BWH-T: Brigham and Women’s Hospital Tumor Staging System 
BWFH: Brigham and Women’s Faulkner Hospital 
MGH: Massachusetts General Hospital 
APR: Abdominoperineal resection 
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Introduction:1  
Squamous Cell Carcinoma (SCC) is a malignant tumor of epidermal keratinocytes. 
It is an extremely common cancer, second in the United States only to basal cell 
carcinomas, and comprises approximately 20% of all non-melanoma skin cancers.1 
SCC exists on a spectrum of disease ranging from precursors such as dysplasia and 
carcinoma in-situ (CIS) to locally invasive disease and finally to metastatic disease. 
Because SCC is so common, its incidence is not explicitly tracked as other cancers 
are, and it is thus difficult to accurately estimate to proportion of cases falling into 
each of the above categories. However, previous studies have estimated that there 
are between 186,000-419,000 cases of invasive SCC in the US in 2012.2 
Furthermore, the incidence appears to be rising, which may be in part due to 
increased exposure to risk factors, better detection of SCC, and an aging 
population.3  
 
SCC are sometimes classified with respect to domains such as morphology and 
behavior, histologic appearance, and body location. Though SCC were traditionally 
grouped as one entity, there has been increased recognition of the fact that 
differences in any of these domains may play an important role in defining the care 
of patients with these tumors. An example of how such differences may be relevant 
to the care of patients is of central importance in this study. For instance, sun 
exposure (particularly UV exposure, and primarily UVB) has long been implicated 
as the key risk factor for the development of cutaneous SCC’s, though SCCs that 
develop in the perianal region seem to do so without much, if any, UV exposure and 
thus have escaped this dogma.4 Instead, recent research suggests that these 
perianal SCC may have distinct etiologies and that their development is more 
closely related to a unique set of factors such as concurrent HPV infection, 
immunosuppression such as HIV infection, smoking status, or chronic inflammatory 
conditions affecting the perianal region.5-7  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Parts	  of	  this	  work	  were	  previously	  reported	  as	  part	  of	  the	  scholarly	  project	  proposal	  submitted	  to	  Scholars	  in	  Medicine	  Office	  (Halim	  K.,	  Karia	  P.,	  Schmults	  C.	  [2014]	  Scholarly	  Project	  Proposal.	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Because the risk factors for perianal SCC described above are different than those 
of cutaneous SCC, questions have arisen about whether perianal SCC are best 
classified with other cutaneous SCC. Though perianal SCC are currently grouped 
with cutaneous cancers, the risk factor profile for perianal SCC is actually more 
similar to SCC of the anus. In addition to similar risk factors, the behavior of 
perianal SCC has been speculated to more closely mirror that of anal SCC. For 
instance, while cutaneous SCC have an excellent prognosis because they rarely 
metastasize, anal cancers may invade lymphatics and metastasize, leading to a 
worse prognosis.8 This research begins to address whether perianal cancers behave 
more as cutaneous SCC or anal SCC.  
 
Better characterizing the behavior of perianal SCC may improve care in several 
ways. Anal canal SCC, because of its worse prognosis, is predominantly handled by 
gastroenterologist/oncologist teams. Over the years, treatment paradigms in this 
field have shifted towards chemoradiation as opposed to previously preferred 
abdominoperineal resection.9 This treatment modality is in stark contrast to 
cutaneous SCCs which can almost always be treated with resection and without the 
need for chemoradiation because they are inherently unlikely to metastasize.10 
Because of this uncertainty regarding the behavior of perianal SCC, staging, 
classification and ultimately the treatment of these tumors in patients is left to the 
judgment of the practitioner. By unifying and conclusively categorizing these 
tumors, we hope to open the door for additional research pursuits specifically 
targeted at improving the care of these patients. 
 
Cancer staging is a crucial element in the care of the cancer patient for several 
reasons. Primarily, it is a determinant of what types of treatments a patient is 
eligible for. By dividing cancers into stages, it can be known for instance that in 
most cases a localized cancer may not benefit from additional total systemic 
chemotherapy, whereas a more advanced stage cancer has a different risk-benefit 
ratio that may warrant more aggressive diagnostics and therapies. Additionally, 
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staging systems have a prognostic component to them as well, meaning that 
patients with similar disease extents can be followed over time and predict, as a 
whole, how they will fare.  
 
Despite the developing thinking that perianal SCCs may be more similar to anal 
SCC than to cutaneous SCC, this problem is not resolved simply by determining 
which group perianal SCC should belong to. For instance, if clinical practice were to 
start staging perianal SCC by the corresponding anal SCC staging guidelines 
instead of cutaneous staging guidelines, practitioners may find that the anal 
staging guidelines also do not accurately represent perianal SCC. We wondered 
therefore whether either staging system currently in place is adequately suited to 
stage perianal SCC. There is precedent for a unique staging system to be developed 
for SCC of a particular body region, which was done after it was recognized that the 
eyelid, with its own unique anatomical considerations, deserves its own staging 
system for SCC.11,12 This therefore sets a precedent for treating SCCs which arise 
on different body regions differently, and to also develop unique staging system 
which better take into account the salient features of the tumors that arise in the 
perianal area. 
 
The staging system most widely used for cutaneous SCC is the American Joint 
Committee on Cancer (AJCC) system. Also developed within the last few years is 
the Brigham and Women’s Hospital Tumor (BWH-T) system which was found to 
outperform the AJCC guidelines for cutaneous SCC.13 The performance of a staging 
system is judged by three parameters: whether it is distinctive (outcomes vary 
between groups), whether it is homogenous (outcomes are similar within a group), 
and whether it is monotonous (outcomes worsen with progressive stages).13 The 
BWH-T guidelines were able to outperform in these parameters by modifying the 
criteria used to upstage a tumor based on histologic features such as 
lymphovascular invasion and perineural invasion. The BWH-T system was 
developed specifically with these features in mind because they are more predictive 
of aggressive tumors, such as those arising in perianal skin. 
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There is also a set of guidelines from the AJCC on staging practices for anal SCC.  
To the author’s knowledge, these have not been investigated for their ability to 
stage perianal SCC accurately. Sufficient data was collected to stage the cohort of 
perianal tumors by AJCC anal guidelines, AJCC cutaneous guidelines, and the 
modified BWH-T guidelines. As previously discussed, perianal SCC, when staged by 
the current cutaneous SCC staging systems, do not behave as expected in terms of 
disease outcomes, often exhibiting more aggressive behavior than expected for a 
given stage. This has been taken into account in developing a staging system that is 
similar but not identical to the now validated BWH-T system and it may outperform 
any of the existing staging guidelines, because it specifically takes into account the 
features of perianal SCC.  
 
Therefore, the ultimate goals of developing a modified BWH-T staging system were 
to stage perianal SCC independently of cutaneous or anal SCC with better accuracy 
than either set of guidelines can currently offer. We compared the key 
characteristics of an adequate staging system (distinctiveness, homogeneity, 
monotonousness).  
 
An additional aim was to assess and describe the perianal SCC population in a 
systematized way at the Brigham and Women’s Hospital and Massachusetts 
General Hospital, as well as to describe the outcomes of their SCC disease. By 
compiling this information regarding risk factors, recurrences, and outcomes, a 
wealth of knowledge about the course and extent of disease in this patient 
population will be created.  By gathering data on HPV co-infection, 
immunosuppression status, and other key comorbid illnesses, risk factors will be 
identified, some of them potentially modifiable that could be touted as ways to 
lessen the prevalence of perianal disease in the future. Ultimately we hope that this 
study improves the care of patients with perianal SCC.   
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Methods 
The BWH-T staging system was modified to better represent the unique 
considerations of perianal SCCs. Unlike the AJCC anal cancer staging guidelines or 
the AJCC non-eyelid carcinoma guidelines, a greater emphasis was placed on “high-
risk factors” in this system (Table 1). In addition, the threshold for differentiation 
counting as a high-risk factor was changed to have both poor or moderate 
differentiation counting. Tumors of exactly 2cm were also included as a high risk 
factor, whereas the AJCC required tumors to be greater than 2cm.  
 
Once the guidelines were established, the first phase of the project was to do a 
smaller pilot study based on literature reports of applicable SCCs. For this, the 
existing literature was reviewed for all reported cases of anogenital SCC with 
sufficient tumor information and outcome data to accurately stage using the AJCC 
and BWHT systems. Penile and vulvar SCC were excluded from this phase of the 
study because there were a relatively small number of cases in the literature that 
contained all of the necessary data in the publication to include in this study.  
 
During the first phase of the study, approximately 400 abstracts were reviewed, and 
130 papers were read to find 56 cases that were of use in the study. In these 56 
cases, demographic data, staging data, and outcome data was recorded for all of 
them. However, because these 56 cases were divided amongst the three different 
locations (penile, vulvar, and perianal), it was ultimately decided that it would not 
be possible to develop a staging system from such small numbers of patients in 
each.  
 
Therefore this investigation is a retrospective pilot study of patients at a single 
institution of perianal SCC. Due to the relative scarcity of these tumors, a 
prospective study would have taken many years to perform. Patient selection was 
pursued using an RPDR billing code search for “malignant anal neoplasm”. The 
search was limited to the years 2000 through 2009, in order to allow for at least 5 
years of possible follow-up and to also ensure adequate medical record 
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documentation. Three hundred eighty-nine patients were identified from the 
Brigham and Women’s Hospital meeting these criteria and an additional 390 from 
the Massachusetts General Hospital. After excluding duplicates, there were 566 
unique patients.  
 
With 566 total patients in the initial database, it was estimated approximately 20% 
would be included in the final analysis. However upon final analysis, this figure is 
closer to 10%, yielding 52 total patients for inclusion in the study. These 52 medical 
records were reviewed with the aim of gathering demographic information, 
pathological information necessary for staging, and all relevant outcome data.  
 
The most subjective component of the chart review was defining precisely each 
patient’s anatomy with respect to the area in which the tumor arose. SCC may 
develop in the neighboring anal canal or anal mucosa, in which case it is a different 
class of tumor and was excluded from this study (Figure 2). Tumors that arose 
primarily on the perianal skin distal to the anal verge were included. This 
distinction was made by reviewing documentation from examining physicians 
including oncologists, dermatologists, surgeons, and gastroenterologists. Pathology 
reports were also scrutinized to determine the nature of the surrounding tissue (for 
instance, mucosa vs hair-bearing skin). Radiology reports were sometimes utilized 
as well for detailed information regarding anatomy.  
 
Patients were also excluded if their tumor was found to be a recurrent one, if they 
did not have a cutaneous perianal SCC as determined above, or if there was 
inadequate documentation in the medical record to gather comorbidities or tumor 
information. 
 
The data was first analyzed qualitatively to compare cohort characteristics with 
respect to local recurrences, nodal recurrence, distant recurrence, disease specific 
death and overall death between the two staging systems. Patients with bad 
outcomes of all types were all scrutinized to identify salient features of their history 
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and tumor characteristics. Given the completely novel nature of this study in the 
SCC literature, a preliminary study that identifies predictive features of morbid 
perianal SCC tumors and demonstrates qualitatively the performance of the BWH-
T system contributes greatly to the SCC body of knowledge. We also performed 
statistical analysis to determine what comorbidities or demographic features might 
independently predict poor outcomes. Finally, we performed a multivariate analysis 
to identify which factors were predictive of poor outcomes.  
 
Data analysis was performed using STATA and was performed at the Brigham and 
Women’s Faulkner Hospital. The work was based out of the Brigham and Women’s 
Faulkner Hospital. All data has been stored securely. There are no other parts of 
this project being conducted by other researchers or groups.   
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Results 
After identifying the initial 566 patients, patient charts were reviewed to determine 
which of the initial patients met inclusion criteria. Of the 779 results in the RPDR 
search, 213 were found to be duplicate patients seeking care at both hospitals. Of 
the remaining 566, twenty-four were excluded due to their diagnosis occurring 
outside the specified study date (2000-2009); 131 were excluded because their 
cancer was not SCC; 220 were excluded because their SCC was deemed to occur at a 
point proximal to the anal verge; 25 were excluded because their tumors were 
recurrent; 51 were excluded because their medical records had inadequate data to 
completely characterize their tumors and outcomes (for instance if only their 
pathology slides were sent to our facility for consultation), as well as “other” 
reasons; 63 were excluded because there was no definite area of invasion in the 
biopsy specimen (Figure 1).  
 
This process left 52 patients to analyze for this study. Baseline cohort demographics 
are presented in Table 2. The patient cohort was predominantly white (90.4%) and 
female (57.7%). The median age at the time of the patient’s diagnostic biopsy was 
55. Forty percent of patients were single, with an equivalent percentage married 
and the remainder were either divorced or widowed. The average time of follow-up 
for patients from date of biopsy was a median of 5.1y, with a range of 0-13.8y. A 
large percentage (38.5%) of patients were immunosuppressed, with the most 
common reasons including documented HIV infection (n=13) and organ transplant 
(n=3). A majority had a documented smoking history (69.2%) and many also were 
documented as being HPV positive at some point either before or after their 
perianal SCC diagnosis (42.3%). Additionally upwards of 30% had some form of 
perianal disease which was defined as inflammatory bowel disease (both Crohn’s 
and Ulcerative Colitis), hemorrhoids, fissures, and genital condyloma, with in 
excess of half of these comprised by condyloma. Twenty-two patients (42%) had been 
diagnosed with another cancer before or during their SCC follow-up.  
 
	   12	  
With regards to staging, a consensus stage was reached for 45 of the 52 tumors 
using the AJCC cutaneous and anal staging system and 46 of the 52 tumors using 
the BWH-T staging system. The majority of the tumors were stage T1 in all groups 
(n=27, AJCC cutaneous; n=31, AJCC Anal; n=22, BWH-T). However, while the 
remainder of the stageable tumors were classified as T2 in the AJCC system (n=18 
cutaneous; n=13 anal), the remaining tumors in the BWH-T system were split 
between the groups T2a (n=15) and T2b (n=9).  
 
Tumors were an average of 1.84cm in diameter, though ranged from 0.2cm tumors 
with small foci of invasive SCC to a large 9.5cm tumor. Tumor differentiation was 
divided between well, moderate and poor, as well as overlapping between two 
divisions, with many tumors being reported as at least partially moderately 
differentiated (n=23). However, 15 tumors were not assigned any degree of 
differentiation in the pathology reports.  Two tumors exhibited some degree of 
lymphovascular invasion under pathologic examination, while none of the pathology 
reports commented on the presence of perineural invasion.  
 
Patients were treated with either resection or chemoradiation, and in some cases 
both. Resection was the only primary treatment modality in 44% of patients (n=23). 
In comparison, 31% (n=16) of patients were treated exclusively with 
chemoradiation. The remainder received some combination thereof, with at least 
part of the tumor being debrided or resected along with chemoradiation treatment 
(n=12). 
 
Bad outcomes were classified as either local recurrences, nodal metastases, distant 
recurrence (metastasis) and death from SCC. There were 6 local recurrences, 2 
nodal recurrences, 4 distant metastases and 3 deaths from SCC. The outcomes were 
both sporadic and progressive; some patients who died from their SCC had local, 
nodal, and distant recurrences prior to death, while one patient had an isolated 
distant metastasis without death or other recurrence.  
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Table 3 demonstrates in detail features of patients with bad outcomes. There were 
10 total patients experiencing at least a local recurrence. Patients with poor 
outcomes appeared to differ in several ways from patients without a poor outcome. 
By qualitative analysis, patients with bad outcomes are in general older, frequently 
immunosuppressed, have very high rates of HPV, other STI, and viral hepatitis co-
infection. There is also a significant minority who have chronic perianal disease or 
inflammation and have been diagnosed with other cancers.  
 
Of the 9 patients who had enough data documented in their charts to be staged, 5 
were assigned a T2 stage by AJCC anal guidelines and 4 were assigned T1 stage.  
There was one T3 AJCC anal tumor in the 52 patient cohort, however this patient 
did not have a poor outcome. AJCC cutaneous guidelines more frequently upstaged 
tumors to T2 than the AJCC anal stage guidelines (7 out of 9 were T2  cutaneous 
stage). However, the BWH-T seemed to most readily upstage this cohort of patient 
tumors, staging only one as a T1 type tumor. Two of the remaining 8 were classified 
as T2a, while 6 of the 9 tumors were designated as T2b tumors.  
 
When we performed a univariate analysis, several factors appeared to be 
independently predictive of a poor outcome. Age >55 (HR 6.0, p<0.05), tumor 
diameter ≥3.0cm (HR 5.5, p<0.05), and tumor invasion into subcutaneous tissue or 
beyond (HR 4.9, p<0.05) were all independently predictive of a poor outcome. When 
we performed a multivariate analysis, age >55 (HR 13.8, p<0.05), tumor diameter ≥
3.0cm (HR 6.1, p<0.05) and HPV infection (HR 4.7, p<0.05) were all predictive of a 
poor outcome.  
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Discussion 
This challenging study endeavored to, for the first time, evaluate the 
appropriateness of different staging systems currently used for staging perianal 
SCC. The ultimate aim of this study was to further the treatment of patients with 
perianal SCC by better defining their tumors and need for various cancer therapies. 
Though there were many challenges, progress was made in achieving some of the 
initial goals.  
 
Our preliminary analysis revealed that for the cohort of patients who had recurrent 
perianal SCC in our study, the Anal AJCC guidelines least frequently predict a bad 
outcome by assigning those tumors a high stage, the Cutaneous AJCC guidelines 
are intermediate in predicting a bad outcome, and the BWH-T guidelines most 
frequently assign a high stage to tumors with eventual poor outcomes. This may be 
due to the restrictive nature of the AJCC guidelines, particularly with respect to 
assigning a high T3 or T4 stage (only one T3 tumor in our 52 patient cohort). This 
means that all poor outcomes occurred in low AJCC tumor stages, and the T3 tumor 
did not have a poor outcome. Conversely, 60% of all the poor outcomes occurred in 
BWH-T high stage (T2b or T3) tumors. This also means however that 40% of the 
high stage tumors according to the BWH-T system did not have a poor outcome. 
 
Though this is encouraging and serves to guide additional investigation, several 
questions remain unanswered. For instance, it may be that BWH-T too readily 
assigns a high stage to tumors, and therefore predicts bad outcomes even for tumors 
that prove to benign. However, our preliminary data suggest this is not a major 
factor; BWH-T staged 9 total tumors of 52 as T2b, of which a majority (6), appeared 
in the final bad outcome cohort. Further research will be required to conclusively 
determine whether this is a favorable tradeoff.  
 
Because of the comprehensive nature of the data collection in this study, it was 
possible to analyze the data for features predictive of poor outcomes. The data 
demonstrate that tumor size, old age, and HPV infection are predictive of poor 
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outcomes in perianal SCC. In addition, patients with poor SCC outcomes have high 
rates of co-morbid conditions including immunosuppressed statuses, other cancers, 
inflammatory conditions of the perianal region, smoking histories, and documented 
HPV positive status. These preliminary findings put in place a framework for future 
studies seeking to develop a predictive model on the basis of the presence of these 
factors. A larger study will be needed to additionally validate the individual 
predictive elements of the staging systems currently in place, with the possible 
exception of tumor diameter which was shown to be predictive in this study. 
 
The high number of bad outcomes (recurrences and death) that occurred in our 
population was surprising. Approximately 20% of patients experienced a poor 
outcome, a proportion far greater than what would be expected for cutaneous SCC, 
again lending credence to the argument that perianal SCC do not behave quite like 
cutaneous SCC. However, caution must be taken in making this claim since the 
selection and classification of these tumors was subject to the biases of a 
retrospective chart review, and may represent tumors that were not truly cutaneous 
tumors.  
 
Also of note in the patient population was the primary treatment modality 
employed. Though abdominoperineal resection (APR) was once the favored 
treatment modality for anal cancers involving the anal sphincter muscles, the 
desire to spare this vital anatomic structure has led to the finding that 
chemoradiation is both safe and effective for patients with anal canal carcinoma.14 
Local resection is still employed for tumors not involving the sphincter, and APR is 
still used as a salvage treatment. In our cohort, a minority actually received 
chemoradiation alone, suggesting that smaller, less invasive tumors were resected 
without chemoradiation, in a manner similar to the treatment of cutaneous SCC. 
However, because this paradigm shift towards chemoradiation occurred in the late 
1990s and into the early 2000’s, we cannot be certain whether patients in the earlier 
part of our cohort were being treated with APR due to the delayed uptake of new 
evidence-based practice guidelines. 
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Among the aforementioned challenges, perhaps foremost are the difficulties posed 
by the complex anatomy of the perianal area (Figure 2) and determining whether a 
tumor arose primarily from perianal, hairbearing skin distal to the anal verge or 
whether it was a tumor of the anal mucosa proximal to the anal verge. There is also 
often confusion regarding terminology and the distinction between the anal verge 
and the anal margin: according to the World Health Organization, the anal verge is 
the most proximal part of the anal margin where the squamous epithelium of the 
anal canal meets the skin and then extends 5cm outwards.15 Tumors of the anal 
margin were included in the study, those involving the anal epithelium and 
proximal were not. 
 
Compounding this anatomical confusion is the fact that the anal verge is more of an 
embryonic boundary, and is not made readily on clinical grounds as compared with 
boundaries such as the dentate line. As a result surgeons use more appreciable 
boundaries when operating in order to define the anal canal, such as the anorectal 
ring. Finally, the focus of invasive SCC rarely arises in otherwise healthy tissue. 
Many times the site would be listed as “anal polyp”, “anal condyloma”, or “arising 
within an anal fissure”. All of these outgrowths are not inherent to any anatomical 
region, and leave much uncertainty as to their origin and how the tumor should be 
ultimately classified. We feel strongly that a consensus should be reached regarding 
terminology and clear definitions be proposed that are not merely anatomically 
accurate but also are practically useful in clinical medical practice. 
 
It is perhaps not surprising then that after looking at several different documents in 
the medical record, rarely was there a consensus regarding the origin of the tumor. 
The same tumor could be described differently by each the dermatologist, surgeon, 
or gastroenterologist, and all may have a different opinion than the oncologist or 
pathologist. Opinions regarding the origin of the tumor also change as additional 
data come in, as is often the case following resection of a perianal tumor, which 
after inspection of the pathologic specimen removed may be a tumor which is clearly 
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a tumor arising from the anal canal. Other times, the analysis is complicated by 
areas of invasive SCC arising in a bed of SCCIS, leading the practitioner to wonder 
if there is invasive SCC elsewhere in the bed of SCCIS that simply was not biopsied 
or resected.  
 
Judgments regarding treatment in these ambiguous cases may be influenced by the 
frequency and availability of biopsy. Even if the invasive SCC biopsy is taken from 
perianal skin, the existence of SCCIS extending into the anal canal does not 
preclude the fact that the tumor may in fact have a mucosal component.  In these 
scenarios, it is perhaps reasonable for the clinician to adopt a defensive stance, and 
to treat any unresolvable ambiguity regarding a tumor as evidence of its mucosal 
origin and proceed to chemoradiation therapy as opposed to simple excision. While 
this practice undoubtedly has the patient’s best-interests in mind (with regards to 
trying to achieve cure and minimize the odds of recurrence or spread in the future) 
it is uncertain based on the data currently available in the literature whether this 
practice achieves its end. What it does clearly do however is expose patients to the 
additional risks of chemoradiation, while perhaps sparing them the risks/harms of 
resection. The cost/benefit ratio of this substitution is also unknown, however we 
suggest that this serve as a major area of future investigation.  
 
Perhaps the most eloquent statement of what we know and what remains 
ambiguous is found written in a patient note, quoted below:  
 
“Although there is literature supporting local excision for perianal lesions that 
involve the skin without involving the anal canal, for true anal canal lesions local 
excision is associated with a higher recurrence rate than chemo-radiation, and for 
this reason chemotherapy and radiation is the standard treatment recommendation. 
Although one of the excisions did describe hair follicles in the specimen, the surgeon 
describes the primary lesion as a polyp within the rectum, and rectal mucosa was 
also visible in the excision. I have had the opportunity to review the pathology 
specimens with Dr. [redacted], who confirmed that there was invasive squamous cell 
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carcinoma arising in a background of anal carcinoma in situ, and that the lesion 
was not based in the perianal skin.” 
 
Therefore, this speculative though collaborative approach may be imperfect. 
Perhaps then it is most prudent to do what physicians do in other situations that 
are also ambiguous, and this is to leave it up to patients to decide the best course of 
action, after informing them what we know and what the known risk/benefits of 
each strategy are. Furthermore, a greater emphasis should be placed on resolving 
this ambiguity through improved communication between providers, for instance by 
forming committees that would decide how to treat ambiguous tumors.  
 
Communication with patients and between patients can only be viewed as a 
temporizing measure, until further research can be performed in patients whose 
tumors continue to elude standard classification even after the above measures 
have been undertaken. This research will likely need to take the form of prospective 
randomized study that splits patients with ambiguous tumors into a 
chemoradiation arm and a surgical resection arm. While the primary outcome of 
such a study should be mortality, an important secondary outcome should be some 
measure of adverse effects and quality of life of treatment, since one treatment may 
be more morbid than the other and thus preferable to certain patients in certain 
scenarios.  
 
An additional major challenge encountered in this study is the often incomplete 
documentation in both the clinical history and pathology reports. In order to 
accurately stage a tumor using the AJCC system, the maximal diameter and depth 
in centimeters of the tumor must be known, as well as the degree of differentiation, 
depth with regards to level of tissue invaded, presence of perineural invasion, and 
site of the tumor. For the BWH-T system, it is also important know whether there is 
lymphovascular invasion. Pathology reports often simply reported “SCC, invasive” 
as the diagnosis without additional information. These reports were assumed to be 
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complete, and therefore if a parameter was not specifically commented on it was 
assumed to be negative or absent.  
 
Records of tumor size varied greatly between practitioners, and while pathology 
reports consistently defined the size of the specimen, the specimen was most likely 
not representative of the tumor (the specimen was either a biopsied portion of the 
tumor, or if removed en masse, contained non-tumor tissue as well). Therefore we 
suggest that when reporting histological aspects of a tumor and also in recording its 
size, there is a clear need for standardization of the reporting format by 
practitioners. Doing so will ensure appropriate staging for clinical purposes, but 
also allow for more precise future research.  
 
Limitations to this study are the fact that this is a single institution study 
performed at a tertiary care hospital that was highly representative of elderly white 
patients, though perhaps less so of other groups and in other geographic regions. 
Therefore the generalizability of our results remains left to be determined. It was 
also a retrospective study in which the results were subject to bias, though steps 
were taken to minimize this effect whenever possible. We also have a relatively 
small cohort of patients, owing to the rarity of the disease in question. There were a 
small number of bad outcomes for patients which likely means that our population 
was underpowered to truly measure the full benefit of the BWH-T guidelines.  
 
Further limitations include the limited expertise of some researchers in the 
medical, surgical, and oncologic management of perianal SCC. This is particularly 
important to this study because a thorough and accurate evaluation of candidate 
patients is necessary to establish a valid patient cohort. There are also only a 
limited number of practitioners involved in the care of these patients and practice 
patterns of the practitioners may not be representative of the population as a whole.  
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Table 1. Summary of the American Joint Committee on Cancer Anal and Cutaneous Squamous Cell Carcinoma 7th Edition 
Staging Guidelines and the Brigham and Women’s Hospital Tumor Staging System for Cutaneous Squamous Cell Carcinoma 
AJCC Anus 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ (i.e., Bowen disease, high-grade squamous intraepithelial lesion, and anal intraepithelial neoplasia II–III) 
T1 Tumor ≤2 cm in greatest dimension 
T2 Tumor >2 cm but ≤5 cm in greatest dimension 
T3 Tumor >5 cm in greatest dimension 
T4 Tumor of any size invades adjacent organ(s), e.g., vagina, urethra, and bladder 
AJCC Cutaneous Squamous Cell Carcinoma 
  TX Primary tumor cannot be assessed 
  T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor ≤2 cm in greatest dimension with <2 high-risk features 
T2 Tumor >2 cm in greatest dimension or tumor any size with ≥2 high-risk features* 
T3 Tumor with invasion of maxilla, mandible, orbit, or temporal bone 
T4 Tumor with invasion of skeleton (axial or appendicular) or perineural invasion of skull base 
BWH Cutaneous Squamous Cell Carcinoma 
T1 
T2a 
T2b 
T3 
0 high-risk factors† 
1 high-risk factor 
2-3 high-risk factors 
4 high-risk factors or bone invasion 
Abbreviations: AJCC, American Joint Committee on Cancer; BWH, Brigham and Women’s Hospital; *AJCC high-risk factors include >2 mm thickness, Clark level ≥IV, 
primary site ear, primary site non-hair-bearing lip, and poorly differentiated histology; †BWH high-risk factors include tumor diameter ≥2 cm, poorly differentiated histology, 
perineural invasion ≥0.1 mm, or tumor invasion beyond fat (excluding bone invasion which automatically upgrades tumor to BWH stage T3).  	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Table 2. Baseline Cohort Characteristics 
Patient Characteristics No. of Patients (n=52) 
Age, mean (standard deviation) 55 (12.7) 
Sex, n (%) 
     Female 
     Male 
 
30 (57.7) 
22 (42.3) 
Race, n (%) 
     White non-Hispanic 
     African American 
     Hispanic or Latino 
 
47 (90.4) 
3 (5.8) 
2 (3.8) 
Marital status, n (%) 
     Single 
     Married 
     Divorced 
     Widowed 
 
21 (40.4) 
22 (42.3) 
5 (9.6) 
4 (7.7) 
Smoking, n (%) 
     No 
     Yes 
 
16 (30.8) 
36 (69.2) 
Human papillomavirus infection, n (%) 
     No 
     Yes 
 
30 (57.7) 
22 (42.3) 
History of hepatitis, n (%) 
     No 
     Yes 
 
44 (84.7) 
8 (15.3) 
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Table 2. Baseline Cohort Characteristics (Continued) 
Patient Characteristics No. of Patients (n=52) 
History of sexually transmitted infection, n (%) 
     No 
     Yes** 
          Human immunodeficiency virus 
          Herpes simplex virus 
          Syphilis 
          Gonorrhea 
          Chlamydia 
 
38 (73.1) 
14 (26.9) 
12 (85.7) 
2 (14.3) 
2 (14.3) 
1 (7.1) 
1 (7.1) 
Immunosuppressed, n (%) 
     No 
     Yes 
          Human immunodeficiency virus 
          Organ transplant 
          Other* 
 
32 (61.5) 
20 (38.5) 
12 (57.1) 
3 (14.3) 
5 (28.6) 
History of perianal disease, n (%) 
     No 
     Yes** 
          Hemorrhoids  
          Condyloma 
          Fissures 
          Inflammatory bowel disease 
          Lichen simplex 
          Lichen sclerosus 
          Perirectal fistula 
 
36 (69.2) 
16 (30.8) 
8 (50.0) 
2 (12.5) 
2 (12.5) 
3 (18.8) 
1 (6.3) 
1 (6.3) 
1 (6.3) 
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Table 2. Baseline Cohort Characteristics (Continued) 
Patient Characteristics No. of Patients (n=52) 
Other cancer diagnosis, n (%) 
     No 
     Yes 
          Kaposi’s Sarcoma 
          Vulvar cancer 
          Non-melanoma skin cancer 
          Anal canal cancer 
          Prostate cancer 
          Breast cancer 
          Endometrial sarcoma 
          Hodgkin’s lymphoma 
          Lung cancer 
          Oropharyngeal cancer 
          Renal cancer 
 
30 (57.7) 
22 (42.3) 
4 (18.2) 
4 (18.2) 
4 (18.2) 
2 (9.1) 
2 (9.1) 
1 (4.6) 
1 (4.6) 
1 (4.6) 
1 (4.6) 
1 (4.6) 
1 (4.6) 
Tumor Characteristics No. of Tumors (n=52) 
Tumor diameter (cm), mean (standard deviation) 1.8 (1.6) 
Depth of tumor invasion, n (%) 
     Dermis 
     Subcutaneous fat 
     Submucosa 
     Muscle 
     Unknown/not recorded 
 
15 (28.9)  
3 (5.8) 
1 (1.9) 
4 (7.7) 
29 (55.7) 
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Table 2. Baseline Cohort Characteristics (Continued) 
Tumor Characteristics No. of Tumors (n=52) 
Tumor differentiation, n (%) 
     Well 
     Moderate 
     Poor 
     Unknown/not recorded 
 
13 (25.0) 
16 (30.8) 
9 (17.3) 
14 (26.9) 
Perineural invasion, n (%) 
     No 
     Yes 
 
51 (98.1) 
1 (1.9) 
Lymphovascular invasion, n (%) 
     No 
     Yes 
 
50 (96.2) 
2 (3.8) 
Primary treatment, n (%) 
     Resection 
     Radiation and chemotherapy 
     Resection, radiation and chemotherapy 
     Resection and radiation 
 
23 (44.2) 
16 (30.8) 
12 (23.1) 
1 (1.9) 
Imaging studies, n (%) 
     No 
     Yes 
          CT 
          PET 
          MRI, CT and PET 
          MRI and PET 
 
13 (25.0) 
39 (75.0) 
32 (82.1)  
5 (12.8) 
1 (2.6) 
1 (2.6)   
 
 
	   28	  
Table 2. Baseline Cohort Characteristics (Continued) 
Tumor Characteristics No. of Tumors (n=52) 
AJCC anal cancer tumor (T) stage, n (%) 
     T1 
     T2 
     T3 
     Indeterminate 
 
31 (59.6) 
13 (25.0) 
1 (1.9) 
7 (13.5) 
AJCC cutaneous squamous cell carcinoma tumor (T) stage, n (%) 
     T1 
     T2 
     Indeterminate 
 
27 (51.9) 
18 (34.6) 
7 (13.5) 
BWH cutaneous squamous cell carcinoma tumor (T) stage, n (%) 
     T1 
     T2a 
     T2b 
     Indeterminate 
 
22 (42.3) 
14 (26.9) 
10 (19.2) 
6 (11.6) 
*Other reasons for immunosuppression include: chronic obstructive pulmonary disease (1), chronic renal failure (1), and psoriatic arthritis (1); **Percentages 
may not add to 100 because some patients had more than one type of condition.  
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Table 3. Characteristics of Patients that had a Poor Outcome during the Study Period 
Patient Age Sex Immunosuppression HPV STI Perianal Disease Primary Treatment Outcome(s) Tumor (T) Stage 
AJCC 
Anal 
AJCC 
Cutaneous 
BWH 
Cutaneous 
1 74 M Y: chronic renal failure Y N N Resection LR, DM, DD T1 T2 T2b 
2 83 F N N N N Resection LR T2 T2 T2a 
3 55 F N N N Y: hemorrhoids Resection, Radiation LR -- -- -- 
4 56 M Y: HIV Y Y: HSV, HIV N Radiation, 
Chemotherapy 
LR T1 T1 T2a 
5 86 F N N N Y: hemorrhoids, lichen simplex Resection NM T1 T2 T2b 
6 62 M N Y N N Resection NM T2 T2 T2b 
7 40 F N Y N N Resection, Radiation, 
Chemotherapy 
DM, DD T2 T2 T2b 
8 82 F N N Y: Syphilis N Radiation, 
Chemotherapy 
DM T2 T2 T2b 
9 49 F Y: psoriatic arthritis Y N Y: hemorrhoids Radiation, 
Chemotherapy 
LR, DM, DD T2 T2 T2b 
10 64 M N N N N Resection, 
Chemotherapy 
LR T1 T1 T1 
Abbreviations: HPV, human pappiloma virus; STI, sexually transmitted infection; AJCC, American Joint Committee on Cancer; BWH, Brigham and Women’s Hospital; HIV, human immunodeficiency virus, HSV, herpes simplex 
virus; LR, local recurrence; NM, nodal metastasis; DM, distant metastasis; DD: death from disease.
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Table 4. Results of Univariate Analysis of Risk Factors Associated with Poor Outcomes* 
Variable HR (95% CI) p value 
Age, years 
     <55 
     ≥55 
 
1.0 
6.0 (1.3-28.4) 
 
 
0.024 
Sex 
     Female 
     Male 
 
1.0 
0.8 (0.2-2.9) 
 
 
0.740 
Smoking 
     No 
     Yes 
 
1.0 
0.3 (0.1-1.2) 
 
 
0.097 
HPV infection 
     No 
     Yes 
 
1.0 
1.4 (0.9-4.9) 
 
 
0.210 
Immunosuppressed 
     No 
     Yes 
 
1.0 
0.7 (0.2-2.7) 
 
 
0.591 
History of perianal disease 
     No 
     Yes 
 
1.0 
1.3 (0.3-5.1) 
 
 
0.738 
History of other cancer 
     No 
     Yes 
 
1.0 
0.7 (0.2-2.6) 
 
 
0.637 
Tumor diameter, cm 
     ≤2.0 
 
1.0 
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     >2.0 -<3.0 
     ≥3.0 
1.1 (0.1-6.1) 
5.4 (1.4-20.7) 
0.884 
0.013 
Table 4. Results of Univariate Analysis of Risk Factors Associated with Poor Outcomes* 
Variable HR (95% CI) p value 
Tumor depth 
     Dermis 
     Subcutaneous fat and beyond 
 
1.0 
4.9 (1.3-18.6) 
 
 
0.018 
Histologic differentiation 
     Well 
     Moderate 
     Poor 
 
1.0 
1.7 (0.3-8.5) 
3.4 (0.7-15.3) 
 
 
0.514 
0.118 
Perineural or lymphovascular invasion 
     No 
     Yes 
 
1.0 
2.5 (0.3-19.9) 
 
 
0.389 
Primary treatment 
     Resection 
     Radiation + chemotherapy 
     Resection + radiation + chemotherapy 
 
1.0 
1.6 (0.4-6.2) 
0.5 (0.1-4.8) 
 
 
0.535 
0.571 
*Poor outcomes include local recurrence, nodal metastasis, distant metastasis and death from disease; Abbreviations: HR, hazard 
ratio; CI, confidence interval.  
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Table 5. Results of Multivariate Analysis of Risk Factors Associated with Poor Outcomes* 
Variable HR (95% CI) p value 
Age, years 
     <55 
     ≥55 
 
1.0 
13.8 (2.4-31.0) 
 
 
0.004 
HPV infection 
     No 
     Yes 
 
1.0 
4.7 (1.1-20.6) 
 
 
0.043 
Tumor diameter, cm 
     <3.0 
     ≥3.0 
 
1.0 
6.1 (1.5-24.3) 
 
 
0.011 
*Poor outcomes include local recurrence, nodal metastasis, distant metastasis and death from disease; Abbreviations: HR, hazard 
ratio; CI, confidence interval.  
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Table 6. Poor Outcomes by the American Joint Committee on Cancer and Brigham and Women’s Hospital 
Tumor Staging Systems*  
Tumor (T) Staging System Risk of Poor 
Outcomes 
p value 
AJCC anus, n (%) 
     T1/T2 (44) 
     T3 (1) 
 
20.5% 
0.0% 
 
 
-- 
AJCC cutaneous, n (%)† 
     T1 (31) 
     T2 (14) 
 
12.9% 
35.7% 
 
 
0.111 
BWH cutaneous, n (%) 
     T1/T2a (36) 
     T2b/T3 (10) 
 
8.3% 
60.0% 
 
 
0.001 
*Poor outcomes include local recurrence, nodal metastasis, distant metastasis and death from disease; †A comparison between low T 
stage (T1/T2) and high T stage (T3/T4) could not be made because no tumors were classified as high T stage.  
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Figure	  2:	  Anatomy	  of	  Perianal	  Skin	  and	  Anal	  Canal	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Figure	  1:	  Reason	  For	  Exclusion	  and	  Final	  Cohort	  
	  	   	  
• 213	  excluded	  as	  duplicate	  patients	  Initial	  Cohort	  IdentiFied	  through	  RPDR	  search	  "malignant	  anal	  neoplasm"	  between	  2000-­‐2009	  n=779	  
• 24:	  Diagnosis	  outside	  2000-­‐2009	  	  • 131:	  Non-­‐SCC	  Cancer	  • 220:	  Location	  Proximal	  to	  anal	  Verge	  or	  elsewhere	  • 25:	  Recurrent	  Tumors	  • 50:	  Inadequate	  Data	  or	  Other	  • 63	  No	  DeFinitive	  Invasion	  
Patients	  Charts	  Reviewed	  For	  Inclusion	  Criteria	  n=566	  
Final	  Cohort	  n=53	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